Search results | gilead

Gilead Sciences

Gilead Sciences is a top pharmaceutical company based in California, USA. The company was founded in 1987. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Since its inception in 1987, the company has primarily concentrated on antiviral drugs to treat patients infected with HIVhepatitis B, or influenza. In 2006, Gilead completed…

Gilead Sciences collaborates with Indian pharma partners for antiretroviral therapy

Gilead Sciences, together with Mylan Laboratories, Ranbaxy Laboratories Limited and Strides Arcolab, have entered into a pharma partners agreements to collaborate on promoting access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries – including single tablet regimens containing emtricitabine, and fixed-dose combinations of emtricitabine co-formulated with other Gilead HIV medicines. Under t…

In a M&A deal, Gilead Sciences acquired YM Biosciences for $510 million

Gilead Sciences and YM BioSciences have signed a definitive m&a agreement under which Gilead will acquire YM for U.S.$2.95 per share in cash. Under the terms of this m&a agreement, upon closing of the proposed transaction, shareholders of YM will receive U.S.$2.95 per common share in cash. Others including holders of warrants and stock options will receive a cash payment equal to the difference between U.S.$2.95 and the exercise price of…

Gilead and Cancer Genetics are biopharma partners

Cancer Genetics and Gilead Sciences, a big pharma company, are now biopharma partners where Cancer Genetics is providing clinical trial services and molecular profiling of chronic lymphocytic leukemia patients. CGI will leverage its SelectOne program that includes proprietary genomic assays in CLL, data and logistics management, and comprehensive CLIA- and CAP-accredited clinical laboratory testing. The trials cover both national and internation…

Gilead and Teva reach settlement agreement for Viread

Gilead and Teva Pharmaceuticals, two top big pharma companies, have reached a settlement agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate). Viread (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement agreement, Teva will be allowed to launch a generic version of Viread on December 15, 2017. Th…

Big pharma Gilead shake hands with AnaptysBio in antibody pharma partnering

Gilead Sciences, a big pharma company has inked a pharma partnering deal with AnaptysBio to develop antibody therapeutics. Antibodies generated by AnaptysBio using its proprietary SHM-XEL platform will be transferred to Gilead for worldwide development and commercialization. Under this pharma partnering agreement, Gilead has paid an up-front fee and will provide research funding to AnaptysBio through the antibody-generation process. AnaptysBio i…

Big pharma Gilead signs R&D pharma partnering deal with Adimab

Adimab and Gilead Sciences, a top big pharma company  have initiated a pharma partnering research collaboration to identify therapeutic antibodies against two targets selected by Gilead. Adimab and Gilead have initiated a pharma partnering research program whereby Adimab will use its proprietary discovery platform to identify fully human antibodies against up to two targets selected by Gilead. The pharma partnering agreement gives Gilead the opt…

Gilead Sciences partnering

Gilead Sciences is a top pharmaceutical company based in California, USA. The company was founded in 1987. Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Since its inception in 1987, the company has primarily concentrated on antiviral drugs to treat patients infected with HIVhepatitis B, or influenza. In 2006, Gilead completed…

Gilead buys biologics plant from Genentech

Gilead has announced that the company will purchase a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech. The agreement covers Genentech’s Oceanside Clinical Plant (OCP), as well as certain other process development assets. “This acquisition represents a unique opportunity to establish Gilead’s biologics process research and manufacturing capability while bringing on a…

Gilead Sciences: M&A activity 2005-2013

Gilead Sciences has also announced 9 M&A deals since 2005, with the lead deals being the acquisition of Pharmasset and Myogen. Abstracted from: Report: Partnering Agreements with Gilead Sciences 2005-2013 Gilead Sciences is involved in M&A activity for growth similar to its peers in the list of top pharmaceutical companies. Gilead Sciences has on occasions sought growth through strategic acquisition, for example when acquiring Pharmasset…

bannerpng
nlsd2014jpg
biovision-300-x-150gif
RSS Feed Linked In Twitter

Latest Tweets

ca300x150gif
current-partnering-300x150jpg
ft-us-healthcare300x150gif